Press Release Global Vascular raises a total of 1.17 billion yen in Series A funding

https://hasebe.med.u-tokai.ac.jp/, group leader: Koizumi Hasebe), a medical-engineering collaborative research team, since the 2000s. We have sublimated the biomaterial “fluoridated diamond-like carbon coating (F-DLC)”, which has been researched and developed in Japan, into a technology that can be implemented on the surface of nickel titanium (NiTi) stents used in the lower limbs, and we have developed a technology that can be implemented on the surface of nickel titanium (NiTi) stents used in the lower limbs. We have achieved the
minimization of “foreign body reactions between living organisms and artificial objects.” We aim to deliver the world’s first
next-generation stents to medical sites around the world by
comprehensively carrying out everything from research and engineering to marketing, commercialization, and obtaining manufacturing and sales approval, including specialists who are familiar with treatment guidelines. .
■Use of proceeds
1. Animal testing at the U.S. GLP testing facility, non-clinical testing in Japan and overseas
・Conduct safety tests and drug dynamic tests at the largest animal testing facility in the United States.
・Conduct engineering, CMC tests, etc. at domestic and overseas facilities. 2. Preparation for the start of the clinical trial
・Make preparations to proceed to clinical trials promptly after obtaining non-clinical trial data.
・Discuss with regulatory authorities the sufficiency of data and the appropriateness of clinical trial protocols.
■Comments from investors
[Image 2

Tanaka Kikinzoku Group Group CEO Koichiro Tanaka
The “stent delivery system for lower extremity arteriosclerosis” developed by Global Vascular was developed by Mr. Hasebe, a
world-renowned researcher in the development of endovascular treatment devices, using the excellent stent design technology and high functionality that he has accumulated over the years. This can be said to be the culmination of surface modification technology. I am very happy to be able to work with the team and related parties who have a high level of awareness and passion, including CEOs Mr. Bito and Mr. Maekawa, who are expected to be part of the leadership of this market in the future.
Through this investment, we hope to promote our research and business and deliver the technology we are developing to patients with lower extremity arteriosclerosis around the world as soon as possible. [Image 4

Mitsubishi UFJ Capital Co., Ltd. Life Science Department
Deputy Director Yosuke Izawa
Stent placement has become popular as a treatment method for arteriosclerosis, but the area below the knee is a harsh environment with narrow blood vessels, slow blood flow, and large vascular deformities, making it extremely difficult to develop. There are currently no effective stents available. After many years of research at HRG, Global Vascular has achieved multiple technological
breakthroughs, such as sublimating F-DLC to a technology that can be mounted on the surface of a NiTi stent, and is now developing a stent that is expected to be effective in the below-knee area. It was successful. In addition to the company’s advanced technical
capabilities, I was exposed to the high level of expertise, passion, and sincere personality of all the members, and I am confident that these members will be able to lead this project to success and save many patients. We have made an investment this time.
We will do our best to support the company’s business growth by making full use of MUFG’s network.
■From the representative director
Representative Director and CEO Kenta Bito
[Image 7